Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EBT: 2011-2025

Historic EBT for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to -$1.0 million.

  • Sunshine Biopharma's EBT fell 3.94% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 58.28%. This contributed to the annual value of -$5.4 million for FY2024, which is 30.60% down from last year.
  • Per Sunshine Biopharma's latest filing, its EBT stood at -$1.0 million for Q3 2025, which was up 48.42% from -$2.0 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's EBT peaked at $667,116 during Q4 2021, and registered a low of -$23.3 million during Q4 2022.
  • For the 3-year period, Sunshine Biopharma's EBT averaged around -$1.2 million, with its median value being -$1.0 million (2023).
  • Within the past 5 years, the most significant YoY rise in Sunshine Biopharma's EBT was 161.55% (2021), while the steepest drop was 6,461.84% (2021).
  • Sunshine Biopharma's EBT (Quarterly) stood at $667,116 in 2021, then crashed by 3,589.50% to -$23.3 million in 2022, then surged by 95.58% to -$1.0 million in 2023, then crashed by 122.09% to -$2.3 million in 2024, then decreased by 3.94% to -$1.0 million in 2025.
  • Its EBT stands at -$1.0 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$1.2 million for Q1 2025.